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Introduction
Molecular targeted therapy with monoclonal antibodies and 
low molecular weight inhibitors have gained increasing importance 
particularly in the treatment of malignant tumors. Sorafenib (Nexavar®) 
is an oral multikinase inhibitor that blocks tumor cell proliferation 
and angiogenesis and is used for the treatment of advanced renal 
cell carcinoma, hepatocellular carcinoma, and other solid tumors 
including metastatic differentiated thyroid cancer, at a starting dose of 
400 mg twice daily [1-4]. The most common adverse effects are fatigue, 
diarrhea, and various other dermatologic  side effects [1]. Recently, a 
meta-analysis of dermatological toxicities associated with sorafenib 
has been published, [5] and a hand-foot-skin reactions (HFSR) was 
most often found, but also rash/desquamation, alopecia, pruritus and 
dry skin. Nail involvement has been reported, in particular sub-ungual 
splinter hemorrhages [6]. We describe a patient with longitudinal 
melanonychia and blue lunulae that developed during sorafenib 
therapy of metastatic thyroid carcinoma.
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Case Report
A 51-year-old woman had a diagnosis of well differentiated papillar 
thyroid carcinoma, stage IV, with multiple gross bone metastases.  She 
had undergone total thyroidectomy subsequently to several courses of 
radioiodine (I131). Four years later, the disease progressed with new bone 
lesions and pulmonary metastasis.  The disease was classified as resistant 
to radioiodine treatment. Orthopedic surgery of the spine was performed 
twice (D10-D11 and L-L4).  Other therapeutic options were evaluated and 
the patient began a treatment with sorafenib, 400 mg twice daily.
After four weeks of continuous treatment, she developed diffuse 
pruritus and facial erythema with dysesthesia and noticed intensive hair 
loss. On physical examination, we found longitudinal melanonychia of 
the left great toe nail (Figure 1) and a bluish discoloration of the lunulae 
was evident in both great toenails (Figure 2). The patient denied to have 
had similar nail alterations before and any recent medication changes.
Discussion
Several cutaneous side effects have been reported with sorafenib 
[1,5-10]. A meta-analysis to determine the type, incidence and risks 
of dermatological toxicities associated with sorafenib treatment of 
advanced solid tumors, usually at a starting dose of 400 mg twice daily, 
showed that the most frequent dermatological adverse effects were 
hand-foot-skin reactions (HFSR) (39.0%), rash/desquamation (35.4%), 
alopecia (25.5%), pruritus (14%) and dry skin (14,1%). The HFSR is 
clinically distinct from the well-known chemotherapy-induced hand-
foot syndrome, because it presents as painful symmetrical erythematous 
and edematous areas on the palms and/or soles commonly associated 
with paresthesias, but the erythema turns thick with desquamation and 
sometimes callus-like hyperkeratosis, particularly but not exclusively 
on pressure areas [7]. No significant correlation between HFSR severity 
and response to treatment was seen [7].
 Other cutaneous adverse effects include facial/scalp erythema/
dysesthesias, a keratosis pilaris-like eruption and more rarely eruptive 
keratoacanthomas, nevi, cysts, inflamed actinic and seborrheic 
keratoses.
Nail involvement has been reported [1,2,5-10], mainly multiple, 
painless subungual splinter hemorrhages. These hemorrhages usually 
developed 2 to 4 weeks after the onset of therapy and are probably 
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Figure 1: Longitudinal melanonychia.
 
Figure 2: Blue discoloration of the lunula.
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related to inhibition of vascular endothelial growth factor receptor 
[6]. Our patient presented with diffuse pruritus, facial erythema with 
dysesthesia, pronounced effluvium and peculiar nail involvement. 
Besides a longitudinal melanonychia on the left great toenail, a bluish 
discoloration of the lunulae was present in both great toenails. To 
our knowledge, the appearance of blue lunulae has not been reported 
before with sorafenib.
Skin toxicities of sorafenib are mainly mild or moderate as they 
usually do not require drug withdrawal [5-10]. Sometimes they require 
dose modifications and/or treatment interruptions [11]. Increased 
awareness by dermatologists who work with oncologists, of the 
diversity, frequency, and treatment of sorafenib-induced cutaneous 
adverse reactions will be helpful for patients who require long-term 
therapy with this medication for their cancers.
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